Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease

NCT06175767 is registered in ClinicalTrials.gov with Mthera Pharma Co., Ltd. as lead sponsor.

NCT NCT06175767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06175767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease
Lead sponsor
Mthera Pharma Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 14, 2025
Completion date
September 30, 2025
Enrollment
120 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease